Maccabi Healthcare Services Reports Findings in Inflammatory Bowel Disease (Trends in Biochemical Parameters, Healthcare Resource and Medication Use in the 5 Years Preceding IBD Diagnosis: A Health Maintenance Organization Cohort Study): Digestive System Diseases and Conditions – Inflammatory Bowel Disease

2022 OCT 25 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- New research on Digestive System Diseases and Conditions - Inflammatory Bowel Disease is the subject of a report. According to news reporting out of Tel-Aviv, Israel, by NewsRx editors, research stated, “Few data describing pre-diagnosis changes in patients with inflammatory bowel disease (IBD) exist. We aimed to determine if there is a pattern of change in use of health resources, medications and laboratory results in the years preceding diagnosis.”

Financial support for this research came from Takeda Pharmaceutical Company.

Our news journalists obtained a quote from the research from Maccabi Healthcare Services, “This retrospective study used electronic medical records of Maccabi Health Services (MHS). Patients with IBD 16 years of age and minimum of 5-years follow-up were identified by entry into the MHS IBD registry and included in the analysis. Demographic, clinical, medication and laboratory data were collected. Generalized estimating equation model was applied to study trends and compare between years. This study included 5643 patients with IBD. Of these, 3039 (53.8%) had Crohn’s disease (CD), 2322 (41.1%) had ulcerative colitis (UC) and 282 (5%) had indeterminate colitis (IC). Laboratory parameters including white blood cells, platelets and C-reactive protein showed significant increases while haemoglobin and mean cell volume showed significant decreases in mean values in the 2 years prior to diagnosis with stable values prior to that (p < 0.0001). Parameters such as creatinine, total protein and albumin showed significant, progressive decreases in mean values starting 5 years prior to diagnosis (p < 0.0001). Patients with CD had distinct laboratory trends when compared with patients with UC. Changes in laboratory parameters, healthcare service and medication use occur during the 5-year period before IBD diagnosis.”

According to the news editors, the research concluded: “These data can have future clinical applicability by developing a composite score and referral algorithm introducing red flags into primary care visits and appropriate referral for specialist care.”

This research has been peer-reviewed.

For more information on this research see: Trends in Biochemical Parameters, Healthcare Resource and Medication Use in the 5 Years Preceding IBD Diagnosis: A Health Maintenance Organization Cohort Study. Digestive Diseases and Sciences, 2022. Digestive Diseases and Sciences can be contacted at: Springer, Van Godewijckstraat 30, 3311 Gz Dordrecht, Netherlands. (Springer - www.springer.com; Digestive Diseases and Sciences - http://www.springerlink.com/content/0163-2116/)

Our news journalists report that additional information may be obtained by contacting Nathaniel A. Cohen, Maccabi Institute for Research & Innovation, Maccabi Healthcare Services, Weizmann Street, Tel Aviv, Israel. Additional authors for this research include Efrat Kliper, Noa Zamstein, Tomer Ziv-Baran, Matti Waterman, Gabriel Hodik, Amir Ben Tov and Revital Kariv.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1007/s10620-022-07714-2. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the journal Digestive Diseases and Sciences is: Springer, Van Godewijckstraat 30, 3311 Gz Dordrecht, Netherlands.

(Our reports deliver fact-based news of research and discoveries from around the world.)